US Patent 9,192,615: Minocycline Extended-Release Formulation Scope, Validity, and Patent Landscape

US Patent 9,192,615 protects specific 65 mg and 115 mg oral extended-release minocycline dosage forms. The claims require a defined lactose/HPMC matrix, a narrow HPMC specification, a fixed carrier ratio, and dissolution performance in 0.1 N hydrochloric acid. The patent is materially narrower than a general patent covering extended-release minocycline. Its commercial relevance is concentrated in Solodyn-type 65 mg and 115 mg products and in generic products that reproduce the claimed formulation or dissolution profile.

What does US Patent 9,192,615 cover?

The patent claims an oral dosage form containing either 65 mg or 115 mg of minocycline. The formulation uses:

Lactose monohydrate as an extragranular fast-dissolving carrier.
Lactose monohydrate as an intragranular fast-dissolving carrier.
Hydroxypropylmethylcellulose, or HPMC, as an intragranular slow-dissolving carrier.
HPMC with 40 to 60 centipoise viscosity.
HPMC having approximately 8.9% hydroxypropoxylation, within a stated plus-or-minus 0.2% range, or approximately 9.1% hydroxypropoxylation.
An extragranular lactose-to-intragranular HPMC ratio of 0.30 to 0.50.
A specified minocycline dissolution profile in 0.1 N HCl.

Claims 1 and 3 are independent composition claims. Claim 1 covers the 65 mg form, while claim 3 covers the 115 mg form. Claims 2 and 4 add a film coating requirement.

Claim	Dose	Core subject matter	Additional coating limitation
1	65 mg	Lactose/HPMC matrix with specified ratio, HPMC characteristics, and dissolution	None
2	65 mg	Claim 1 formulation	Coating equal to 3.5%-4.0% of dosage-form weight
3	115 mg	Lactose/HPMC matrix with specified ratio, HPMC characteristics, and dissolution	None
4	115 mg	Claim 3 formulation	Coating equal to 3.0%-3.3% of dosage-form weight

The patent does not claim every extended-release minocycline product. It claims a particular formulation architecture and performance result.

How broad are the independent claims?

The independent claims are combination claims with several mandatory limitations. A competing product would generally need to satisfy every limitation of claim 1 or claim 3 to create a literal infringement case.

Required dosage strength

The claims are limited to 65 mg and 115 mg of minocycline. They do not directly cover:

45 mg minocycline products.
90 mg minocycline products.
135 mg or other strengths.
Products containing a different amount of active ingredient unless the amount falls within a legally applicable interpretation of the claimed quantity.

This dosage limitation is commercially important because Solodyn was marketed in multiple strengths. The patent does not provide a complete blocking position across all extended-release minocycline strengths.

Required placement of lactose

The claims require two distinct lactose monohydrate populations:

An extragranular fast-dissolving carrier.
An intragranular fast-dissolving carrier.

A formulation containing lactose only intragranularly, only extragranularly, or using a different fast-dissolving excipient may avoid literal infringement of this limitation.

The claim language also creates a potential evidentiary issue. The parties would likely need to establish whether the accused product’s manufacturing process and final dosage form contain the claimed intra- and extragranular distribution. Finished-product testing may not always independently reveal the original granulation location of an excipient.

Required intragranular HPMC

HPMC must be present as an intragranular slow-dissolving carrier. A formulation using HPMC only as a coating, only outside the granules, or as a different release-control polymer would present a noninfringement position.

The claim is not limited to one trade-grade HPMC, but the polymer must satisfy both chemical-substitution and viscosity requirements.

HPMC substitution and viscosity

The claim requires HPMC with:

Approximately 8.9% hydroxypropoxylation, with a stated tolerance of plus or minus 0.2%; or
Approximately 9.1% hydroxypropoxylation; and
Viscosity of 40 to 60 cps.

This limitation excludes many HPMC grades that differ materially in hydroxypropoxyl content or viscosity. It also creates a technical dispute over:

The analytical method used to measure hydroxypropoxylation.
Whether “about 9.1%” is interpreted with the same tolerance as the expressly stated 8.9% plus-or-minus 0.2% range.
The test method and temperature used for viscosity.
Whether the relevant viscosity is measured for the raw material or under another specified condition.

Required carrier ratio

The ratio of extragranular fast-dissolving carrier to intragranular slow-dissolving carrier must be 0.30 to 0.50.

This is a narrow formulation parameter. A ratio below 0.30 or above 0.50 would generally support a literal noninfringement argument, subject to claim construction and the doctrine of equivalents.

The ratio is also potentially vulnerable to measurement disputes because the claim does not, in the supplied text, specify whether the ratio is calculated by weight, on a dry basis, or using the total quantity of each excipient category. Patent specifications commonly resolve this issue through definitions and examples.

What dissolution profile does the patent require?

The claims use dissolution performance as a substantive limitation, not merely as a product-development objective.

HPMC specification	1 hour	2 hours	3 hours	4 hours
8.9% hydroxypropoxylation, plus or minus 0.2%	About 37%	About 61%	90%	Not specified
About 9.1% hydroxypropoxylation	About 41%	About 68%	About 90%	About 100%

The testing medium is 0.1 N HCl. That condition is important. Dissolution results generated in water, phosphate buffer, or another gastric-fluid simulation may not establish whether the claim is met.

The terms “about 37%,” “about 61%,” “about 41%,” and similar language introduce claim-construction questions. The patent specification, examples, prosecution history, and relevant Federal Circuit case law would be important in determining the permitted numerical range. A generic manufacturer could argue that its product falls outside the claimed profile even if it has broadly similar extended-release behavior.

What formulations are protected by claims 2 and 4?

Claims 2 and 4 add a coating limitation to the respective 65 mg and 115 mg formulations.

The 65 mg formulation must have a coating equal to 3.5% to 4.0% of the dosage-form weight.
The 115 mg formulation must have a coating equal to 3.0% to 3.3% of the dosage-form weight.

These claims are narrower than claims 1 and 3. A product that satisfies claim 1 or claim 3 but falls outside the applicable coating range would not infringe the dependent claim, although it could still infringe the independent claim.

The coating limitation may be difficult to assess where the product contains multiple coating layers, colorants, polishing agents, or moisture-barrier materials. The relevant question would be whether those materials are included in the claimed “coating” weight under the patent’s specification and prosecution history.

When does US Patent 9,192,615 lose exclusivity?

US Patent 9,192,615 was issued on November 24, 2015. Its patent term is based on the applicable nonprovisional filing and priority dates, rather than the issue date. The nominal expiration is in 2031, generally identified as May 19, 2031, before any applicable patent-term adjustment or regulatory extension.

Event	Date
Patent issued	November 24, 2015
Nominal patent-term endpoint	May 19, 2031
Relevant commercial products	Extended-release oral minocycline, particularly 65 mg and 115 mg strengths
Regulatory exclusivity type	Small-molecule drug exclusivity, not biologic exclusivity

Patent expiration does not necessarily equal the date on which generic competition began. Earlier patents, settlements, regulatory exclusivity, authorized-generic arrangements, and the terms of ANDA approvals can produce different commercial entry dates.

What is the Orange Book status of US Patent 9,192,615?

The patent is associated with the Solodyn extended-release minocycline product line and its formulation patent estate. Orange Book relevance depends on the specific NDA, listed strength, and use code recorded by FDA.

An Orange Book listing does not establish patent validity. It gives FDA a patent notice for ANDA certification purposes. A listed formulation patent can trigger a Paragraph IV notice and potential Hatch-Waxman litigation, but it does not prevent a court from finding the patent invalid, unenforceable, or not infringed.

The commercial significance of the patent is strongest for an ANDA applicant seeking approval of a 65 mg or 115 mg extended-release minocycline product with the same or substantially similar matrix design. The risk is lower where the ANDA formulation uses:

A different polymer.
A different HPMC grade.
A materially different carrier ratio.
A different granulation architecture.
A dissolution profile outside the claim.
A different strength not covered by the claims.

Which companies challenged the Solodyn patent estate?

Solodyn and related extended-release minocycline products attracted generic competition from multiple manufacturers. Publicly reported generic participants included Actavis, Mylan, Par Pharmaceutical, and other ANDA sponsors over the product’s lifecycle.

The key legal pathway was the Paragraph IV certification. An ANDA applicant could certify that the listed patent was invalid, unenforceable, or would not be infringed. The NDA holder could then file a patent infringement action within 45 days of receiving notice, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework. FDA approval and commercial launch depended on the specific patent certifications, litigation outcomes, settlements, and regulatory status of each applicant.

Because US Patent 9,192,615 issued after some earlier Solodyn litigation began, it should be analyzed as part of a continuation and follow-on patent strategy rather than as the only patent affecting generic entry.

What patent litigation affects US Patent 9,192,615?

The relevant litigation risk is cumulative. A generic applicant may face:

Earlier Solodyn formulation patents.
Later continuation patents.
Method-of-use patents.
Trade-secret or manufacturing disputes.
Regulatory exclusivity and labeling restrictions.

The existence of a prior Solodyn settlement does not necessarily eliminate the risk created by a later-issued continuation patent. Settlement terms may include a license date, a no-challenge provision, a product-specific launch date, or rights limited to particular strengths.

For an ANDA diligence review, the critical documents are the Orange Book patent list, Paragraph IV notice, complaint, answer, claim-construction record, settlement agreement, and any consent judgment. The patent’s claim language alone cannot establish whether a particular generic applicant obtained a license or an agreed launch date.

Does the patent create biosimilar risk?

No. Minocycline is a small-molecule antibiotic. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.

The relevant competition risks are:

Paragraph IV ANDA challenges.
Paragraph III certifications with delayed approval.
Authorized-generic competition.
Formulation redesigns.
State substitution rules.
Commercial entry after patent expiry or settlement.

How strong is the patent estate?

Strengths

The patent has meaningful technical specificity:

It covers two commercially relevant strengths.
It combines composition, manufacturing-location, polymer, ratio, and dissolution limitations.
The dissolution profile can distinguish the claimed product from a conventional immediate-release formulation.
The claims are directed to measurable product attributes, which can support comparative testing in litigation.

Weaknesses

The claim scope is narrow:

Only 65 mg and 115 mg doses are expressly covered.
The formulation must contain lactose in two specified locations.
HPMC chemistry and viscosity are constrained.
The carrier ratio is limited to 0.30 to 0.50.
The dissolution profile must be assessed in a specified acid medium.
Prior-art combination references could challenge obviousness based on known minocycline matrices, lactose granulation, HPMC grades, and controlled-release dissolution targets.

The central validity question would be whether the claimed combination was nonobvious over prior extended-release minocycline formulations and conventional pharmaceutical matrix technology. The more the prosecution history relied on the precise dissolution profile, the more important reproducibility and analytical testing become.

How does US Patent 9,192,615 compare with other minocycline patents?

Patent category	Typical protection	Relevance to generic entry
Early extended-release minocycline patents	Broad matrix concepts and controlled release	May expire earlier but can define the prior-art field
US 9,192,615	65 mg and 115 mg lactose/HPMC formulations with specific dissolution	Direct formulation risk for matching products
Method-of-use patents	Treatment of acne or other dermatologic conditions	Risk depends on the proposed ANDA labeling
Manufacturing patents	Granulation, blending, compression, or coating processes	Often harder to assess from public product information
Later continuations	Narrower formulation or dosage claims	May extend practical litigation risk after earlier patents expire

What generic launch scenarios exist?

Scenario 1: Literal formulation match

A generic applicant reproduces the claimed 65 mg or 115 mg formulation, HPMC specification, carrier ratio, and dissolution profile. This presents the highest infringement risk.

Scenario 2: Same therapeutic profile, different formulation

The applicant achieves comparable extended release using a different polymer, excipient distribution, or granulation process. The product may avoid literal infringement, although the doctrine of equivalents remains a potential issue.

Scenario 3: Different strength

A 45 mg or 90 mg product is outside the express dosage limitations of claims 1 through 4. Other patents or regulatory restrictions may still apply.

Scenario 4: Product outside the dissolution range

A formulation that releases minocycline materially faster or slower may avoid the claim, but the result must be demonstrated using the claimed 0.1 N HCl method and a defensible interpretation of “about.”

What is the commercial exposure?

Solodyn was a major branded dermatology product before generic erosion. Its commercial exposure was concentrated in acne treatment and in the 45 mg, 65 mg, 90 mg, and 115 mg extended-release strengths. The 65 mg and 115 mg strengths covered by US 9,192,615 represented only part of the product line, limiting the patent’s standalone revenue protection.

The commercial value of the patent depended on the combined estate. Earlier patents could delay generic entry before US 9,192,615 became the principal barrier. After those patents expired or were licensed, this patent could still affect a generic formulation designed to match the branded release profile.

Key Takeaways

US Patent 9,192,615 is a narrow formulation patent, not a broad minocycline patent.
Claims 1 and 2 cover 65 mg dosage forms; claims 3 and 4 cover 115 mg dosage forms.
The claims require intra- and extragranular lactose, intragranular HPMC, 40-60 cps viscosity, defined hydroxypropoxylation, a 0.30-0.50 carrier ratio, and specific acid dissolution.
Claims 2 and 4 add narrow coating-weight ranges.
The patent’s nominal expiration is in 2031, generally identified as May 19, 2031.
It is relevant to generic Solodyn-type products but does not cover all minocycline strengths or all extended-release formulations.
The main legal vulnerabilities are claim narrowness, prior-art obviousness, analytical reproducibility, and proof of excipient location in the finished product.
Minocycline competition is governed by the ANDA and Paragraph IV framework, not the biosimilar pathway.
Generic entry analysis must consider the full Solodyn patent estate, Orange Book listings, settlements, and later continuation patents.

FAQs about US Patent 9,192,615

Does US Patent 9,192,615 cover immediate-release minocycline?

No. The claims require an extended-release matrix with specified carrier placement, HPMC characteristics, carrier ratio, and dissolution performance.

Does the patent cover 90 mg Solodyn?

Not under the supplied claims. Claims 1 through 4 are limited to 65 mg and 115 mg dosage forms.

Can a generic avoid the patent by using another controlled-release polymer?

Potentially. A formulation using another polymer may avoid the express HPMC limitation, although infringement would depend on the complete formulation and any doctrine-of-equivalents analysis.

Are the dissolution percentages independent patent limitations?

Yes. The stated dissolution results are part of the claimed dosage-form definition and can be material to infringement and validity disputes.

Is US Patent 9,192,615 a composition patent or a method-of-use patent?

It is principally a composition and dosage-form patent. The supplied claims do not require administering minocycline to a patient or treating a disease.

References

U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,192,615, minocycline oral dosage form.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certifications.
U.S. Food and Drug Administration. (n.d.). Solodyn: Minocycline hydrochloride extended-release tablets, prescribing information.
United States Code, 35 U.S.C. §§ 154, 156, and 271.
United States Code, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-004	Jul 23, 2009		DISCN	Yes	No	9,192,615	⤷ Start Trial	Y				⤷ Start Trial
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-005	Jul 23, 2009		DISCN	Yes	No	9,192,615	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428	⤷ Start Trial
Canada	2613273	⤷ Start Trial
China	101208097	⤷ Start Trial
European Patent Office	1898925	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,192,615

Which drugs does patent 9,192,615 protect, and when does it expire?

Summary for Patent: 9,192,615